FDA Fast-Tracks Psychedelic Drugs for Mental Health

0:00It's April 24th. This is Canada News Today, powered by AI. I'm Cory with the story. The FDA just dropped a big move, fast-tracking three psychedelic drugs for tough mental health battles like depression and PTSD. They handed out priority review vouchers to two companies working on psilocybin from magic mushrooms for treatment-resistant depression and 1-4. Methalone, tied to MDMA, aimed at post-traumatic stress. These vouchers cut review times from months down to weeks, though approval is not locked in. This ramps up from President Trump's executive order last weekend, pushing federal agencies to ease up on psychedelics despite their illegal status. Under federal law, Health Secretary Robert F. Kennedy Jr. has been all-in, promising access for hard psychiatric cases within a year, echoing his push last July, too. Trump's base, including combat vets and the Make America Healthy Again crowd, is cheering this shift toward mind-altering treatments once shunned by.

1:02Big pharma. Meanwhile, Democrats in Congress are raising eyebrows, questioning a voucher's favorite White House picks, especially those cutting drug prices. On top of that, the FDA GreenLid early tests for a safer version of eyeball gain from an African plant targeting alcohol use disorder without the heart. Democrats of the original, Silicon Valley cash, like from Peter Teal, is fueling startups racing for approvals on these schedule-one substances long seen as no-go medically. As psychedelics gained traction beyond the fringes, this could reshape mental health options, blending old-school plants with cutting-edge science for. Democrats who've run out of roads.